Skip to main content
BSEM
NASDAQ Life Sciences

BioStem Q3 Loss Widens to $11.4M; Cash Falls to $1.0M as Guidance Is Raised

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.31
Mkt Cap
$24.274M
52W Low
$1
52W High
$8.4
52W Position info
31% above low
Off High info
84% below high
Rel. Volume info
2.1× avg
Market data snapshot near publication time

BSEM sits 31% above its 52-week low of $1 on elevated volume (2.1× avg).

Summary

BioStem posted a $11.4M Q3 net loss on $7.6M of revenue with cash down to $1.0M, but raised full-year revenue guidance to $28M-$29M and outlined $10M-$12M of annualized cost cuts.


Key Events · Earnings and Guidance · BSEM

  • Q3 Revenue Falls, Loss Widens

    Net revenue was $7.6M versus $10.5M a year earlier, and the GAAP net loss was $11.4M, or $0.64 per share, compared with net income of $0.8M in Q3 2025.

  • Cash Drops to $1.0M

    Cash and equivalents fell to $1.0M at September 30, 2026 from $7.0M at June 30, 2026, with $8.8M used in operations during the quarter.

  • Full-Year Guidance Raised

    Full-year 2026 revenue guidance was raised to $28M-$29M from the prior $26M-$29M range.

  • Cost Cuts of $10M-$12M Planned

    A cost reduction plan is being finalized, expected to cut annualized cash operating expenses by roughly $10M-$12M versus the current run rate, with full benefit beginning in Q1 2027.


Analysis · BSEM · Life Sciences

The headline is deteriorating fundamentals: Q3 net revenue fell to $7.6M from $10.5M a year ago, and the GAAP net loss widened to $11.4M, or $0.64 per share. Cash dropped to $1.0M from $7.0M in the prior quarter, and the $10.0M Clearance Payment owed to BioTissue remains unpaid and is being renegotiated. Against that, management raised full-year revenue guidance to $28M-$29M and is finalizing a plan to cut $10M-$12M of annualized cash operating expenses, with full benefit starting in Q1 2027. The company is leaning on the $40M Roth equity facility, but sales under it cannot begin until early April 2027 unless the restriction is waived, so near-term liquidity depends on the BioTissue restructuring and the cost cuts.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BSEM was trading at $1.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.3M. The 52-week trading range was $1.00 to $8.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BSEM - Latest Insights

BSEM
Nov 12, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.37
Real-time Price: $1.08 info
Change: -$0.2899 (-21%) info
Market Cap: $24.274M info
BSEM
Nov 12, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.30
Real-time Price: $1.08 info
Change: -$0.2224 (-17%) info
Market Cap: $24.274M info
BSEM
Sep 30, 2026, 4:48 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.09
Real-time Price: $1.08 info
Change: -$2.01 (-65%) info
Market Cap: $24.274M info
BSEM
Sep 29, 2026, 4:56 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $3.83
Real-time Price: $1.08 info
Change: -$2.75 (-72%) info
Market Cap: $24.274M info
BSEM
Sep 18, 2026, 5:24 PM EDT
Filing Type: S-1
Importance Score:
7
Price at Filing: $4.74
Real-time Price: $1.08 info
Change: -$3.66 (-77%) info
Market Cap: $24.274M info